News for NextCure, Inc. (NXTC)

NextCure (NXTC) is making steady progress with its LNCB74 antibody-drug conjugate program. The company successfully completed the second cohort in April 2025 as

Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. ( NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing

**media[585926]**

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. ( NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing

**media[511700]**

NextCure stock hits 52-week low at $0.99 amid market challenges

NextCure stock hits 52-week low at $1.00 amid market challenges

BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. ( NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. ( NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer  Annual Meeting

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...

The IDH inhibitors market is expected to grow significantly in the coming years. This is due to the rising occurrence of IDH-mutated cancers, such as acute...

PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the global burden of cancer...

The PD-1 and PD-L1 inhibitor market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The acute myeloid leukemia market has a promising outlook with emerging therapies. The overall dynamics of the acute myeloid leukemia market are...